The evidence behind MiYOSMART myopia management lenses

HOYA puts evidence front and centre for MiYOSMART myopia management lenses

HOYA Vision Care has launched a global Confidence Through Evidence campaign, bringing attention to the robust and extensive evidence that supports the confident use of MiYOSMART spectacle lenses in everyday practice.

MiYOSMART spectacle lenses are based on the revolutionary Defocus Incorporated Multiple Segments (D.I.M.S.) technology developed in collaboration with The Hong Kong Polytechnic University in 2014.

To date, MiYOSMART is supported by over 25 scientific publications with the highest number of publications (vs. abstract in congresses) in peer-reviewed academic journals. MiYOSMART lenses are the subject of a highly successful 6-year follow-up clinical study – the longest on a myopia management spectacle lens – which shows their myopia control effects are sustainable over time, with no rebound effect if lens use is stopped.¹

In addition, HOYA Global Medical Affairs team is now conducting a 3-year observational study in the United Kingdom (UK). This new study reached its 1-year milestone early this year, with the results officially presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 conference on the 23rd-27th of April, in New Orleans.²  The results of the study demonstrated similar effectiveness of MiYOSMART spectacle lenses in Caucasian versus Asian children, particularly in children aged 8 to 13 years .^{2, 3} Most children were symptom-free within one week, showing great tolerability and acceptance.²

“It’s important to choose treatments to slow the progression of myopia in children based on best evidence available”, said Professor Saw Seang Mei from Singapore Eye Research Institute, in one of the campaign expert interviews published by HOYA Vision Care on the social media portal, LinkedIn.

HOYA Vision Care is committed to evidence-based myopia management and strives to bring this approach to the next level by empowering Eye Care Professionals in their clinical practice. They action this commitment through their new Confidence through Evidence campaign. The campaign aims to educate Eye Care Professionals on the importance of evidence in childhood myopia, as well as bringing attention to the robust MiYOSMART evidence, which will allow Eye Care Professionals to confidently manage myopia in their everyday clinical practice.

Over 2 million parents across the world have already trusted MiYOSMART, since its launch in 2018.⁴ With the MiYOSMART evidence extending to European cohort, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.

Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of Myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.